Navigation Links
Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager

SAN DIEGO, Jan. 8 /PRNewswire/ -- Amira Pharmaceuticals, a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory diseases, today announced the appointment of Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager to its Scientific Advisory Board. This further strengthens the Board that includes Professor Frank Austen (Professor of Respiratory and Inflammatory diseases, Harvard Medical School), Professor Sally Wenzel (Professor of Medicine, University of Pittsburgh), and Professor Joseph Witztum (Professor of Medicine, University of California, San Diego).

Dr. Paul Anderson has more than 40 years of pharmaceutical research and managerial experience. He spent 30 years at Merck Research Laboratories. He retired from Merck in 1994 and joined DuPont-Merck Pharmaceuticals as Senior Vice President for Chemical and Physical Sciences and later, in 2001, he joined Bristol-Myers Squibb as Vice President for Drug Discovery and Site Head. He retired from BMS in 2002. Dr. Anderson is a past president of the American Chemical Society. Dr. Anderson's contributions to science have been recognized by numerous awards, including the National Academy of Sciences Award for Chemistry in Service to Society, the Perkin Medal from the Society of Chemical Industry and the American Chemical Society's highest honor, the Priestly Medal.

Dr. Jerold Chun is a Professor at The Scripps Research Institute in La Jolla, CA. He is a recognized leader in the field of receptor-mediated Lysophospholipid signaling. Dr. Chun's group studies the development and function of the mammalian nervous system in particular in relation to bioactive lipid signaling. Dr. Chun's group cloned and functionally identified the first lysophospholipid receptor. He has published over 160 manuscripts, and received multiple awards and fellowships including the Medical Scientist Training Program; Grass, Helen Hay Whitney, Alfred P. Sloan, March of Dimes, and Klingenstein Foundations and the National Institutes of Health (NIH). He has been or is currently on editorial boards for multiple scientific journals. He currently sits on scientific advisory boards for Novartis and Cellular Bioengineering, Inc.

Dr. Andrew Tager is an Assistant Professor at Harvard Medical School in the Pulmonary and Critical Care Unit of the Massachusetts General Hospital, and co-director of the hospital's interstitial lung disease program. His research is focused on understanding pulmonary inflammation, lung injury and idiopathic pulmonary fibrosis (IPF). Recently Dr. Tager's laboratory published a seminal paper demonstrating that the lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. The results suggested that lysophosphatidic acid is the chemoattractant predominantly responsible for recruiting fibroblasts into the lungs of IPF patients.

Peppi Prasit, Amira Pharmaceuticals' CSO, commented, "We are delighted to have these three renowned scientists join our advisory board. Amira has an outstanding group of scientific advisors who bring complementary skills and experience to our drug discovery and development programs."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease linked to the phospholipid pathways. Amira has a strategic partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R). The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
2. Amira Pharmaceuticals Appoints First Vice President of Development
3. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
4. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
5. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
6. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
(Date:6/23/2016)... , June 23, 2016 The vast ... an outpatient dialysis facility.  Treatments are usually 3 times ... hours per visit, including travel time, equipment preparation and ... patient, but especially grueling for patients who are elderly ... a skilled nursing and rehabilitation centers for some duration ...
Breaking Medicine Technology: